Abstract
In August 2011 vemurafenib (Zelboraf; Daiichi Sankyo/Roche), an inhibitor of BRAF kinase, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic melanoma with the BRAFV600E mutation.
References
Garbe, C. et al. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 16, 5–24 (2011).
Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002).
Tsai, J. et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl Acad. Sci. USA 105, 3041–3046 (2008).
Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596–599 (2010).
US Food and Drug Administration. FDA labeling information — Zelboraf. FDA website [online], (2011).
Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809–819 (2010).
Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516 (2011).
Boni, A. et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 70, 5213–5219 (2010).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
Keith Flaherty has served on the scientific advisory board for Genentech/Roche.
Rights and permissions
About this article
Cite this article
Flaherty, K., Yasothan, U. & Kirkpatrick, P. Vemurafenib. Nat Rev Drug Discov 10, 811–812 (2011). https://doi.org/10.1038/nrd3579
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3579
- Springer Nature Limited
This article is cited by
-
Computational biophysics approach towards the discovery of multi-kinase blockers for the management of MAPK pathway dysregulation
Molecular Diversity (2023)
-
Physio-pathological effects of m6A modification and its potential contribution to melanoma
Clinical and Translational Oncology (2021)
-
Docking-based structural splicing and reassembly strategy to develop novel deazapurine derivatives as potent B-RafV600E inhibitors
Acta Pharmacologica Sinica (2017)
-
Genetic and Epigenetic Alterations of TERT Are Associated with Inferior Outcome in Adolescent and Young Adult Patients with Melanoma
Scientific Reports (2017)
-
Nifuroxazide exerts potent anti-tumor and anti-metastasis activity in melanoma
Scientific Reports (2016)